Display options
Cite
Kang JS, Park KD, Ahn B, et al. Decreased Diethylnitrosamine-induced Liver Preneoplastic Lesions by Estradiol-3-benzoate Treatment. Toxicol Res. 2011;27(4):247-51doi: 10.5487/TR.2011.27.4.247.
Kang, J. S., Park, K. D., Ahn, B., & Han, B. S. (2011). Decreased Diethylnitrosamine-induced Liver Preneoplastic Lesions by Estradiol-3-benzoate Treatment. Toxicological research, 27(4), 247-51. https://doi.org/10.5487/TR.2011.27.4.247
Kang, Jin Seok, et al. "Decreased Diethylnitrosamine-induced Liver Preneoplastic Lesions by Estradiol-3-benzoate Treatment." Toxicological research vol. 27,4 (2011): 247-51. doi: https://doi.org/10.5487/TR.2011.27.4.247
Kang JS, Park KD, Ahn B, Han BS. Decreased Diethylnitrosamine-induced Liver Preneoplastic Lesions by Estradiol-3-benzoate Treatment. Toxicol Res. 2011 Dec;27(4):247-51. doi: 10.5487/TR.2011.27.4.247. PMID: 24278579; PMCID: PMC3834389.
Copy Download .nbib Format: NLM
Share it on

Toxicol Res. 2011 Dec;27(4):247-51. doi: 10.5487/TR.2011.27.4.247.

Decreased Diethylnitrosamine-induced Liver Preneoplastic Lesions by Estradiol-3-benzoate Treatment.

Toxicological research

Jin Seok Kang, Ki Dae Park, Byeongwoo Ahn, Beom Seok Han

Affiliations

  1. Department of Biomedical Laboratory Science, Namseoul University, Cheonan 330-707, Korea.

PMID: 24278579 PMCID: PMC3834389 DOI: 10.5487/TR.2011.27.4.247

Abstract

To clarify whether inhibitory effect of estrogen on liver tumor is associated with cell proliferation, we investigated its role in diethylnitrosamine (DEN)-induced rat preneoplastic lesions, with time sequenced manners. F344 male rats (n = 90) were divided into three groups at 5 weeks of age. The mini-osmotic pumps providing a continuous infusion of DEN was implanted into the abdominal cavity of each animal in group 1, 2 and 3 at 6 weeks of age. To see the effect of estrogen, pellet containing 1 or 10 μg of estradiol- 3-benzoate (EB) was implanted subcutaneously in the animals of groups 2 or 3, respectively, one week prior to DEN treatment. Ten animals of each group were euthanized at 10, 14 and 18 weeks after DEN treatment. Liver tissues at each time point were fixed in 10% phosphate-buffered formalin and were processed and embedded in paraffin and 5 μm sections mounted on a silanized slide. Glutathione S-transferase placental form (GST-P) positive foci and 5-bromo-2-deoxyuridine (BrdU) labeling cells were detected at each time point. Area of GST-P positive foci in DEN+EB 1 or 10 μg group was significantly decreased compared to DEN alone at 14 weeks (p < 0.01 or p < 0.05, respectively) an at 18 weeks (p < 0.05 or p < 0.01, respectively). BrdU index in DEN+EB 1 or 10 μg groups was significantly decreased compared to DEN alone at 14 weeks and at 18 weeks (p < 0.01). Taken together, we conclude that EB treatment decrease the DEN-induced liver preneoplastic lesions and this may be associated with decrease of cellular proliferation.

Keywords: 5-bromo-2-deoxyuridine (BrdU); Diethylnitrosamine (DEN); Estradiol-3-benzoate (EB); Glutathione Stransferase placental form (GST-P) positive foci; Liver carcinogenesis

References

  1. Toxicol Pathol. 2003 Jan-Feb;31(1):80-6 - PubMed
  2. Mol Cell Endocrinol. 2002 Jul 31;193(1-2):59-63 - PubMed
  3. Mutat Res. 2000 Apr;462(2-3):209-17 - PubMed
  4. Cancer Res. 1990 May 1;50(9):2679-82 - PubMed
  5. Cancer Res. 2007 Dec 1;67(23):11141-6 - PubMed
  6. Carcinogenesis. 1991 Jun;12(6):1133-6 - PubMed
  7. Jpn J Cancer Res. 1994 Jun;85(6):578-83 - PubMed
  8. Semin Liver Dis. 1999;19(3):271-85 - PubMed
  9. Jpn J Cancer Res. 2001 Mar;92(3):249-56 - PubMed
  10. Jpn J Cancer Res. 1988 May;79(5):556-72 - PubMed
  11. Prev Med. 1991 Jan;20(1):15-26 - PubMed
  12. Carcinogenesis. 1989 Jan;10(1):175-81 - PubMed
  13. Cancer Res. 1989 Sep 15;49(18):5044-7 - PubMed
  14. J Biol Chem. 1998 Feb 13;273(7):3838-47 - PubMed
  15. Carcinogenesis. 1995 Nov;16(11):2733-41 - PubMed
  16. Cancer Res. 2000 Sep 15;60(18):5106-10 - PubMed
  17. Toxicol Pathol. 1996 Jan-Feb;24(1):119-28 - PubMed
  18. Cancer Lett. 2001 Jan 10;162(1):117-22 - PubMed
  19. Oncol Rep. 2005 Aug;14(2):377-82 - PubMed
  20. Jpn J Cancer Res. 1988 May;79(5):573-5 - PubMed
  21. IARC Monogr Eval Carcinog Risk Chem Man. 1978 May;17:1-349 - PubMed
  22. Carcinogenesis. 1992 Jun;13(6):979-85 - PubMed
  23. Cancer Res. 1999 Mar 15;59(6):1244-51 - PubMed
  24. Jpn J Cancer Res. 1992 May;83(5):438-44 - PubMed
  25. Gastroenterology. 2007 Jun;132(7):2557-76 - PubMed

Publication Types